Gillian Cannon
CIK: 0001833910
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Jun 5, 2026XENE
Xenon Pharmaceuticals Inc.
Sale(S)Direct1.2K shares at avg. $53.14$63K - Jun 3, 2026XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectRestricted Share Units
1.6K shares- - Jun 3, 2026XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectShare Option (Right to Buy)
10.5K shares- - Jun 1, 2026XENE
Xenon Pharmaceuticals Inc.
Exercise(M)Direct2.6K shares- - Sep 10, 2025CORT
CORCEPT THERAPEUTICS INC
Gift(G)Direct7.4K shares- - Sep 4, 2025CORT
CORCEPT THERAPEUTICS INC
Exercise(M)Direct11K shares at avg. $22.99$253K - Sep 4, 2025CORT
CORCEPT THERAPEUTICS INC
Tax Payment(F)Direct3.6K shares at avg. $70.13$253K - Jun 10, 2025CORT
CORCEPT THERAPEUTICS INC
Award(A)DirectStock option (right to buy)
15K shares- - Jun 5, 2025XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectRestricted Share Units
2.6K shares- - Jun 5, 2025XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectShare Option (Right to Buy)
17K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  XENE Xenon Pharmaceuticals Inc. | Sale(S) | 1,190 | $53.14 | $63,237 | Direct |
| Jun 3, 2026 | XENE Xenon Pharmaceuticals Inc. | Award(A) Restricted Share Units | 1,593 | - | - | Direct |
| Jun 3, 2026 | XENE Xenon Pharmaceuticals Inc. | Award(A) Share Option (Right to Buy) | 10,507 | - | - | Direct |
| Jun 1, 2026 | XENE Xenon Pharmaceuticals Inc. | Exercise(M) | 2,645 | - | $0 | Direct |
| Sep 10, 2025 |  CORT CORCEPT THERAPEUTICS INC | Gift(G) | 7,393 | - | - | Direct |
| Sep 4, 2025 | CORT CORCEPT THERAPEUTICS INC | Exercise(M) | 11,000 | $22.99 | $252,890 | Direct |
| Sep 4, 2025 | CORT CORCEPT THERAPEUTICS INC | Tax Payment(F) | 3,607 | $70.13 | $252,959 | Direct |
| Jun 10, 2025 | CORT CORCEPT THERAPEUTICS INC | Award(A) Stock option (right to buy) | 15,000 | - | - | Direct |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | Award(A) Restricted Share Units | 2,645 | - | - | Direct |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | Award(A) Share Option (Right to Buy) | 17,012 | - | - | Direct |
1-10 of 10 transactions
About Cannon Gillian
Cannon Gillian (SEC CIK 0001833910) files insider reports with the SEC as Director of Xenon Pharmaceuticals Inc. (XENE) and Director of CORCEPT THERAPEUTICS INC (CORT).
Signal8 holds 6 ownership filings by Cannon Gillian, all Form 4s, filed between Jun 6, 2025 and Jun 8, 2026. Those filings report 10 transactions, from Jun 5, 2025 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cannon Gillian's filings is in BURNABY.
Recent filings by Cannon Gillian
- Jun 5, 2026: Open-market sale of XENE shares (Form 4, code S).
- Jun 3, 2026: Grants or awards of XENE derivative securities (2 lines, Form 4, code A).
- Jun 1, 2026: Option exercise of XENE shares (Form 4, code M).
- Sep 10, 2025: Gift of CORT shares (Form 4, code G).
- Sep 4, 2025: Option exercise of CORT shares (Form 4, code M).
Other insiders filing for Xenon Pharmaceuticals Inc. (XENE)
- Kelly Thomas Patrick, Chief Financial Officer
- MORTIMER IAN, PRESIDENT & CEO
- Svoronos Dawn, Director
- GANNON STEVEN, Director
- PATOU GARY, Director
- Machado Patrick, Director